Peterson JG, Roe MT, Topol EJ. GPIIb/IIIa Inhibitors as Primary Therapy for ACS: Lessons from Recent Clinical Trials. Acute Coronary Syndromes 1998: Volume I (4):122-131.
Peterson JG, Lauer MS, Sapp SK, Topol EJ. Heparin Use is Required for Clinical Benefit of GIIb/IIIa Inhibitor Eptifibatide in Acute Coronary Syndromes: Insights from the PURSUIT Trial. Circulation 1998 (Abstract); 98(17):I-360.
Roe MT, Marso SP, Sapp SK, Peterson JG. Empiric use of IIb/IIIa Blockade in Acute Coronary Syndromes: Early and Durable Reduction with Eptifibatide in Patients Who Did Not Undergo Coronary Revascularization. Circulation 1998; 98(17):I-505
Lauer MA, Peterson JG, Arheart KL, Sapp SK. The Effect of Glycoprotein IIb/IIIa Inhibition on Rebound Ischemia Following Discontinuation of Heparin Therapy: Observations from the PURSUIT Trial. Circulation 1998; 98(17):I-767.
Robbins MA, Balog C, Marso SP, Peterson JG. Post-procedural Chest Pain: A Pivotal Indicator of Cardiac Events Following Percutaneous Intervention Independent of ECG Changes. Circulation 1998; 98(17):I-845
The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey.Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating.Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.